SG11202113192QA - Novel tumor-specific antigens for ovarian cancer and uses thereof - Google Patents
Novel tumor-specific antigens for ovarian cancer and uses thereofInfo
- Publication number
- SG11202113192QA SG11202113192QA SG11202113192QA SG11202113192QA SG11202113192QA SG 11202113192Q A SG11202113192Q A SG 11202113192QA SG 11202113192Q A SG11202113192Q A SG 11202113192QA SG 11202113192Q A SG11202113192Q A SG 11202113192QA SG 11202113192Q A SG11202113192Q A SG 11202113192QA
- Authority
- SG
- Singapore
- Prior art keywords
- ovarian cancer
- specific antigens
- novel tumor
- tumor
- novel
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 206010033128 Ovarian cancer Diseases 0.000 title 1
- 206010061535 Ovarian neoplasm Diseases 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962866089P | 2019-06-25 | 2019-06-25 | |
PCT/CA2020/050869 WO2020257922A1 (en) | 2019-06-25 | 2020-06-22 | Novel tumor-specific antigens for ovarian cancer and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202113192QA true SG11202113192QA (en) | 2021-12-30 |
Family
ID=74059840
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202113192QA SG11202113192QA (en) | 2019-06-25 | 2020-06-22 | Novel tumor-specific antigens for ovarian cancer and uses thereof |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220354937A1 (en) |
EP (1) | EP3990483A4 (en) |
JP (1) | JP2022539301A (en) |
KR (1) | KR20220025808A (en) |
CN (1) | CN114026117A (en) |
AU (1) | AU2020301838A1 (en) |
BR (1) | BR112021025943A2 (en) |
CA (1) | CA3141898A1 (en) |
IL (1) | IL288826A (en) |
MX (1) | MX2022000046A (en) |
SG (1) | SG11202113192QA (en) |
WO (1) | WO2020257922A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3109716A1 (en) | 2018-08-30 | 2020-03-05 | Universite De Montreal | Proteogenomic-based method for identifying tumor-specific antigens |
AU2022331944A1 (en) * | 2021-07-16 | 2024-02-01 | Université de Montréal | Novel tumor-specific antigens for cancer stem cells and uses thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003111595A (en) * | 2001-06-25 | 2003-04-15 | Kyogo Ito | Tumor antigen |
EP3777882A1 (en) * | 2013-07-30 | 2021-02-17 | BioNTech SE | Tumor antigens for determining cancer therapy |
GB201511191D0 (en) * | 2015-06-25 | 2015-08-12 | Immatics Biotechnologies Gmbh | T-cell epitopes for the immunotherapy of myeloma |
MY189596A (en) * | 2015-07-15 | 2022-02-18 | Immatics Biotechnologies Gmbh | A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
GB201517538D0 (en) * | 2015-10-05 | 2015-11-18 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
GB201604490D0 (en) * | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides combination of peptides for use in immunotherapy against cancers |
MA47367B1 (en) * | 2017-01-27 | 2023-06-28 | Immatics Biotechnologies Gmbh | NOVEL PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS |
EP3990007A2 (en) * | 2019-06-28 | 2022-05-04 | The Francis Crick Institute Limited | Novel cancer antigens and methods |
-
2020
- 2020-06-22 AU AU2020301838A patent/AU2020301838A1/en active Pending
- 2020-06-22 SG SG11202113192QA patent/SG11202113192QA/en unknown
- 2020-06-22 KR KR1020227001272A patent/KR20220025808A/en unknown
- 2020-06-22 BR BR112021025943A patent/BR112021025943A2/en unknown
- 2020-06-22 CA CA3141898A patent/CA3141898A1/en active Pending
- 2020-06-22 US US17/622,552 patent/US20220354937A1/en active Pending
- 2020-06-22 CN CN202080046241.3A patent/CN114026117A/en active Pending
- 2020-06-22 MX MX2022000046A patent/MX2022000046A/en unknown
- 2020-06-22 WO PCT/CA2020/050869 patent/WO2020257922A1/en unknown
- 2020-06-22 JP JP2021572500A patent/JP2022539301A/en active Pending
- 2020-06-22 EP EP20832110.9A patent/EP3990483A4/en active Pending
-
2021
- 2021-12-09 IL IL288826A patent/IL288826A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2020301838A1 (en) | 2022-02-10 |
EP3990483A4 (en) | 2024-02-21 |
CN114026117A (en) | 2022-02-08 |
US20220354937A1 (en) | 2022-11-10 |
BR112021025943A2 (en) | 2022-02-08 |
KR20220025808A (en) | 2022-03-03 |
IL288826A (en) | 2022-02-01 |
WO2020257922A1 (en) | 2020-12-30 |
CA3141898A1 (en) | 2020-12-30 |
JP2022539301A (en) | 2022-09-08 |
EP3990483A1 (en) | 2022-05-04 |
MX2022000046A (en) | 2022-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL288754A (en) | Compositions and methods for cancer immunotherapy | |
EP3915581A4 (en) | Novel cancer antigens and antibodies of said antigens | |
IL288826A (en) | Novel tumor-specific antigens for ovarian cancer and uses thereof | |
IL289585A (en) | Dll3-targeting antibodies and uses thereof | |
EP3597766A4 (en) | Novel biomarker for cancer immunotherapy | |
IL289269A (en) | Anti-cd24 antibody and uses thereof | |
EP3594365A4 (en) | Biomarker for her2-positive cancer and anti-her2 therapy and use thereof | |
IL284772A (en) | Anti-variable muc1* antibodies and uses thereof | |
SG11202112112UA (en) | Anti-galectin-9 antibodies and uses thereof | |
IL285963A (en) | Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy | |
IL291027A (en) | Anti-steap1 antibodies and uses thereof | |
EP4013460A4 (en) | Smart peptides and transformable nanoparticles for cancer immunotherapy | |
IL283076A (en) | Methods and compositions for cancer immunotherapy | |
EP4045054A4 (en) | Nano-enabled immunotherapy in cancer | |
IL289335A (en) | Novel cancer antigens and methods | |
IL289334A (en) | Novel cancer antigens and methods | |
IL289205A (en) | Novel cancer antigens and methods | |
IL289200A (en) | Novel cancer antigens and methods | |
IL291550A (en) | Anti-il-27 antibodies and uses thereof | |
IL291546A (en) | Anti-kir3dl3 antibodies and uses thereof | |
IL291280A (en) | Anti-cd371 antibodies and uses thereof | |
IL282308A (en) | Novel cancer antigens and methods | |
EP4072580A4 (en) | Personalized tumor vaccine and use thereof for cancer immunotherapy | |
EP4025204A4 (en) | Cancer immunotherapy | |
IL286792A (en) | Compositions and methods for cancer immunotherapy |